Avenzo and DualityBio ink exclusive global license deal

Californian oncology-focused biotech Avenzo Therapeutics and China-based Duality Biotherapeutics (DualityBio) have entered into an exclusive license agreement, whereby Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate (ADC), globally (excluding Greater China).

“DualityBio has a strong track record of developing and advancing a pipeline of differentiated ADCs that target a broad range of indications,” said Dr Athena Countouriotis, co-founder, president and chief executive of Avenzo Therapeutics. “By targeting both EGFR and HER3 with its differentiated design, AVZO-1418/DB-1418 has the potential to provide clinical benefit across multiple solid tumor types. We are excited to add this drug candidate to our clinical pipeline and look forward to collaborating with DualityBio to quickly progress this program into clinical studies,” she added.

Financial terms